Zealand pauses development of GLP-1/GLP-2 obesity candidatenews2025-11-13T11:50:28+00:00November 13th, 2025|Endpoints News|
Novartis says Phase 3 data prove new antimalarial could address resistancenews2025-11-12T22:00:50+00:00November 12th, 2025|Endpoints News|
FDA announces new regulatory pathway for personalized rare disease therapiesnews2025-11-12T22:00:19+00:00November 12th, 2025|Endpoints News|
Pazdur vs. Prasad: Can the CDER-CBER dynamic change under new leadership?news2025-11-12T20:37:57+00:00November 12th, 2025|Endpoints News|
Lilly drops CVS as drug benefits manager — reportnews2025-11-12T20:08:40+00:00November 12th, 2025|Endpoints News|
Chinese biotechs are shedding their fast-follower reputations as innovation surgesnews2025-11-12T18:18:10+00:00November 12th, 2025|Endpoints News|
WuXi AppTec plants ‘flag down’ in Europe with new Munich headquarters news2025-11-12T17:39:33+00:00November 12th, 2025|Endpoints News|
Immatics shares early bispecific data as it seeks to make its name beyond cell therapynews2025-11-12T16:42:44+00:00November 12th, 2025|Endpoints News|
FDA taps Richard Pazdur as new CDER director after Tidmarsh’s resignationnews2025-11-11T21:51:07+00:00November 11th, 2025|Endpoints News|
Why class competition hasn’t brought checkpoint inhibitor prices downnews2025-11-11T19:25:52+00:00November 11th, 2025|Endpoints News|
